Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
REGN5459 had decreased binding affinity to T cells, resulting in an encouraging side effect profile and efficacy.
Check out these advances in blood cancer research and treatment.
Immunotherapy leads the way, along with promising breakthroughs for treating leukemia and multiple myeloma.
Mosunetuzumab is the first bispecific antibody, a type of immunotherapy, approved to treat non-Hodgkin lymphoma.
UPDATE: On October 25, the FDA approved Tecvayli (teclistamab) to treat some people with multiple myeloma.
Eighty percent of participants with relapsed follicular lymphoma responded to a new drug.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.